Francesco DeRubertis

Huge thanks to the great people from @medicxi for founding and getting us here. Double thanks to @fderubertis and @Kevinjohnson360 for the vision to help found it in the first place.

We are excited to announce the launch of Ottimo Pharma, with the appointment of David Epstein as Chair & Chief Executive Officer. He is joined by Mehdi Shahidi, Head of Development & Chief Medical Officer, and James Sabry as Vice Chair of the Board medicxi.com/news/ottimo-ph…

Exciting news for our portfolio company Vaderis who announced positive results from its randomized, double-blind, placebo-controlled Proof-of-Concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia (HHT)

This could be a transformative outcome for patients living with #osteoarthritis, where currently available analgesics are limited by adverse events, addiction liabilities and poor efficacy

Congratulations to @MedicxiKevin and the Levicept team for these positive Phase 2 results for LEVI-04 in #osteoarthritis: levicept.com/wp-content/upl…

In this global multi-centre Phase 2 study of >500 participants, LEVI-04 met all primary and secondary efficacy endpoints with significant analgesia across all measures for all doses vs placebo LEVI-04 was well tolerated, and detailed examination found no increased incidence of rapidly progressive osteoarthritis

Our CEO, Dr. Jayson Dallas, shares with @PharmaVoice how our unique therapeutic approach is focused on metabolic rate, not just weight loss, and has the potential to redefine the treatment landscape for #CardiometabolicDiseases. Read more: bit.ly/3IUnp1T

Itch Session: Updates in the pathophysiology of #Itch presented by @itchdoctor The sensory paradigm of cytokines/JAK signaling, neuro-immune interface, & more at #AAD2024 #SanDiego @EmmaGuttman @IcahnMountSinai

Please join us today at the Dermatology Innovation Forum where I will introduce Alys Pharmaceuticals, a transformative immuno-dermatology innovation engine that I helped to co-found with many others including @HarrisVitiligo @Finlay_Jonny. #skin #itch #vitiligo #alopecia #dermatitis #urticaria advancing-derm.org/platform/confe…

We created Levicept with cofounder Simon Westbrook as a @medicxi newco in 2012. Under a leadership team spearheaded by Eliot and Simon as CSO, we strongly believe that LEVI-04 can effectively target the clinically proven neurotrophin pain pathways with a superior safety profile.

Delighted to welcome @EliotForster as CEO of Levicept. We look forward to working with you on the ongoing phase II studies for Levi-04, our once-a-month injectable for the treatment of osteoarthritis and chronic pain. More details here: lnkd.in/efw-KDVc

Over the next three years, Alys aims to deliver several clinical proof-of-concept readouts and advance at least one program to registrational studies.

The Alys leadership team strongly believe that underserved disease areas, such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements.

We’re proud to announce the launch of Alys Pharma, an immuno-dermatology focused company backed with $100m financing by @medicxi and led by world leading scientific experts dedicated to developing transformative medicines for dermatology patients worldwide bit.ly/3SEhxOI

@MathsNotebook @pronuncemistak 10

A few thoughts about my experience as an academic dermatologist and serial entrepreneur. . . nextstepsinderm.com/derm-topics/to…

@Medicxi has today launched its $400m Medicxi IV fund. The new fund will continue to support drug hunters with clear product visions to deliver transformative #therapies for #patients Read more about the fund here: bit.ly/3KclW87 #Medicxi #MedicxiIV

Congrats to @medicxi portfolio company @VersanisBio on its acquisition by @EliLillyandCo medicxi.com/news/medicxi-a…

Huge strides have been made in the therapeutic management of obesity. @VersanisBio bimagrumab reduces fat mass whilst at the same time increasing muscle mass

Differentiated pharmacology too compelling for @Medicxi partner Nick Williams to pass up when he led our Series A investment <2 years ago